IL317445A - Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use - Google Patents

Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use

Info

Publication number
IL317445A
IL317445A IL317445A IL31744524A IL317445A IL 317445 A IL317445 A IL 317445A IL 317445 A IL317445 A IL 317445A IL 31744524 A IL31744524 A IL 31744524A IL 317445 A IL317445 A IL 317445A
Authority
IL
Israel
Prior art keywords
irak4
conjugation
degradation
methods
inhibitors
Prior art date
Application number
IL317445A
Other languages
Hebrew (he)
Inventor
Huaqing Liu
Dongqing Sun
Zhiwei Wang
Original Assignee
Beigene Ltd
Huaqing Liu
Dongqing Sun
Zhiwei Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd, Huaqing Liu, Dongqing Sun, Zhiwei Wang filed Critical Beigene Ltd
Publication of IL317445A publication Critical patent/IL317445A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL317445A 2022-06-09 2023-06-08 Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use IL317445A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2022097833 2022-06-09
CN2022128219 2022-10-28
CN2023093639 2023-05-11
PCT/CN2023/099146 WO2023237049A1 (en) 2022-06-09 2023-06-08 Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use

Publications (1)

Publication Number Publication Date
IL317445A true IL317445A (en) 2025-02-01

Family

ID=89117516

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317445A IL317445A (en) 2022-06-09 2023-06-08 Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use

Country Status (14)

Country Link
US (1) US20250195513A1 (en)
EP (1) EP4536664A4 (en)
JP (1) JP2025519417A (en)
KR (1) KR20250022796A (en)
CN (2) CN119403805A (en)
AR (1) AR129567A1 (en)
AU (1) AU2023282477A1 (en)
CA (1) CA3258387A1 (en)
CL (1) CL2024003737A1 (en)
CO (1) CO2024018066A2 (en)
IL (1) IL317445A (en)
MX (1) MX2024015184A (en)
TW (1) TW202413351A (en)
WO (1) WO2023237049A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
EP4613748A1 (en) * 2022-11-04 2025-09-10 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. Irak4 degradation agent and use thereof
EP4428134A1 (en) * 2023-03-10 2024-09-11 Dark Blue Therapeutics Ltd Protac degraders of mllt1 and/or mllt3
EP4656640A4 (en) * 2023-03-03 2026-08-19 Shanghai Qilu Pharmaceutical Res And Development Centre Ltd IRAQ-4 DEMOCRAFT AND USE OF IT
US20240374588A1 (en) * 2023-04-07 2024-11-14 Astrazeneca Ab Irak4 protacs
KR20260005340A (en) * 2023-05-30 2026-01-09 상하이 후이룬 파마슈티컬 컴퍼니 리미티드 Tricyclic compounds, methods for preparing the same, and applications thereof
KR20260048566A (en) * 2023-07-13 2026-04-10 인크레랜드 Aromatic compounds, pharmaceutical compositions containing the same, and uses thereof
CN122270449A (en) * 2023-12-13 2026-06-23 百济神州(苏州)生物科技有限公司 Degradation of IRAK4 by conjugation of IRAK4 inhibitors to E3 ligase ligands and methods of use
WO2025149070A1 (en) * 2024-01-10 2025-07-17 甘李药业股份有限公司 Synthesis and use of novel proteolysis chimera compound targeting interleukin-1 receptor-associated kinase 4 (irak4)
WO2026035999A1 (en) 2024-08-09 2026-02-12 Triana Biomedicines, Inc. Anaplastic lymphoma kinase (alk) degraders and uses thereof
WO2026061418A1 (en) 2024-09-18 2026-03-26 Beone Pharmaceutical (Suzhou) Co., Ltd. Dual irak1/irak4 degraders, compositions thereof, and methods of treatment therewith
WO2026158660A1 (en) * 2025-01-26 2026-07-30 甘李药业股份有限公司 Compound for targeted degradation of irak4 protein and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11065231B2 (en) * 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
AU2019389174A1 (en) * 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) * 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021127278A1 (en) * 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20230122219A1 (en) * 2020-02-03 2023-04-20 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN114437035A (en) * 2020-11-06 2022-05-06 海思科医药集团股份有限公司 Compound for inhibiting and degrading IRAK4, pharmaceutical composition and pharmaceutical application thereof
WO2023055952A1 (en) * 2021-09-29 2023-04-06 C4 Therapeutics, Inc. Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds

Also Published As

Publication number Publication date
WO2023237049A1 (en) 2023-12-14
JP2025519417A (en) 2025-06-26
KR20250022796A (en) 2025-02-17
CN120865210A (en) 2025-10-31
CN119403805A (en) 2025-02-07
EP4536664A1 (en) 2025-04-16
EP4536664A4 (en) 2026-08-19
AU2023282477A1 (en) 2024-12-19
CA3258387A1 (en) 2023-12-14
MX2024015184A (en) 2025-02-10
CL2024003737A1 (en) 2025-04-21
TW202413351A (en) 2024-04-01
US20250195513A1 (en) 2025-06-19
CO2024018066A2 (en) 2025-01-13
AR129567A1 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
IL326350A (en) Benzopyridinones and benzopyrimidinones as PI3K inhibitors
AU2024314618A1 (en) Pi3k inhibitors and use thereof
MX2024015184A (en) Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use
SG11202106478UA (en) Compositions for increasing half-life of a therapeutic agent in canines and methods of use
EP3897670A4 (en) MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
IL179514A0 (en) Method of administering and using vegf inhibitors for the treatment of malignant pleural effusion
IL314415A (en) 2-substituted thiazole hsd17b13 inhibitors and uses thereof
IL287220B2 (en) Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CA3251244A1 (en) Pi3k.alpha. inhibitors and methods of use thereof
IL289758A (en) Proportin inhibitors for use in the prevention and treatment of kidney damage
IL289127A (en) Ppm1a inhibitors and methods of using same
SG11202009966SA (en) Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
GB202307609D0 (en) Methods and composition for kras modifications
HK40120789A (en) Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use
EP3952871A4 (en) AKT DEGRADATION BY CONJUGATION OF ATP COMPETITIVE AKT INHIBITOR GDC-0068 WITH E3 LIGASE LIGANDS AND METHODS OF USE
WO2021067572A3 (en) Compositions and methods for inhibiting carp-1 binding to nemo
CA3265397A1 (en) Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
EP3962480A4 (en) Degradation of aurora kinase (aurk) by conjugation of aurk inhibitors with e3 ligase ligand
IL289184A (en) Compositions and methods for preventing and/or reducing melanosis in crustaceans
IL286699A (en) Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers
HK40007999A (en) Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use
HK40008079A (en) Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
EP4021956A4 (en) METHODS FOR REDUCING ALDEHYDE EMISSIONS IN POLYETHER POLYOLS AND POLYURETHANE FOAM
HK40118338A (en) Irak4 degradation agent and use thereof
GB201903349D0 (en) Seawater treatment and injection platform